Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul;34(7):3807-10.

MicroRNA signature for HER2-positive breast and gastric cancer

Han Sung Kang  1 , Sang-Geun Jang  1 , Sun Young Kwon  2 , Young Soo Park  3 , Jeffrey E Green  4 , Hark Kyun Kim  5 , Jungsil Ro  5
Affiliations
  • PMID: 24982406

MicroRNA signature for HER2-positive breast and gastric cancer

Han Sung Kang et al. Anticancer Res. 2014 Jul.

Erratum in

  • Errata.
    [No authors listed] [No authors listed] Anticancer Res. 2015 May;35(5):3109. Anticancer Res. 2015. PMID: 25964603 No abstract available.
  • Errata.
    [No authors listed] [No authors listed] Anticancer Res. 2019 Nov;39(11):6417. Anticancer Res. 2019. PMID: 31704877 No abstract available.

Abstract

Background/aim: The molecular mechanism for aggressive clinical behaviour related to v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2) amplification is not fully-understood. In particular, little is known about microRNAs in the human epidermal growth factor receptor 2 (HER2) signaling network.

Patients and methods: Using microRNA microarray, the microRNA profiles of 16 HER2-positive breast carcinomas were compared with those of five luminal-type breast carcinomas. Additionally, two frozen, ERBB2-amplified gastric carcinomas were compared with their adjacent normal tissue samples. MicroRNAs that were differentially expressed according to the HER2 status in breast and gastric carcinomas were identified as the HER2 microRNA signature.

Results: MiR-337 and miR-302f were commonly overexpressed in HER2-postive breast and gastric cancer. MiR-139 and miR-129 were commonly underexpressed in HER2-positive breast and gastric cancer. A concordant pattern of microRNA expression was noted between discovery sets and the majority of candidate microRNAs (two out of three) in three validation sets.

Conclusion: Our study identified novel microRNAs that were differentially expressed according to the HER2 status across different tumor types.

Keywords: HER2; breast cancer; gastric cancer; miR-129; miR-139.

PubMed Disclaimer

Publication types

LinkOut - more resources